Skip to main content

Advertisement

SpringerLink
Log in

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

We investigated the effect of dosages of paroxetine and cytochrome P450 (CYP) 2D6 genotypes on the plasma concentration of paroxetine in Japanese patients being treated with paroxetine.

Methods

Blood samples were collected from 73 individuals after at least 2 weeks of the same daily dose of paroxetine. The plasma paroxetine concentration was measured using HPLC, and the CYP2D6 genotypes were identified by PCR. Genotype groups were compared by one-way analysis of variance at different paroxetine doses.

Results

The mean plasma paroxetine concentrations at daily doses of 10, 20, 30, and 40 ng/ml were 6.6±7.4, 34.9±26.8, 74.8±37.2, and 130.5±96.8 ng/ml, respectively, showing a disproportionate and nonlinear increase in plasma drug levels of paroxetine upon increasing doses. Plasma paroxetine concentrations in patients with CYP2D6*10 alleles were significantly higher than those without *10 allele at 10 mg/day (7.3±6.11 vs. 2.99±3.52 ng/ml), but there was no significant difference between *1/*1, *1/*10 and *10/*10 genotypes at the higher doses. Similarly, patients with CYP2D6*5 alleles showed higher plasma paroxetine concentrations than those without *5 allele, although differences in the plasma paroxetine concentration did not reach statistical significance level because of the small number of subjects with *5 alleles.

Conclusions

Our results indicate the possibility of saturation in paroxetine metabolism with an increase in paroxetine dose, and that CYP2D6*10 allele(s) have significant impact on plasma paroxetine concentration at low doses in Japanese population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Reference

  1. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 350:60–75

    CAS  PubMed  Google Scholar 

  2. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278–287

    Google Scholar 

  3. Bertilsson L, Dahl ML, Tybring G (1997) Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 391:14–21

    CAS  PubMed  Google Scholar 

  4. Bertilsson L, Dahl ML. 1996 Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 5:200–223

    Google Scholar 

  5. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452–459

    CAS  PubMed  Google Scholar 

  6. Someya T, Shimoda K, Suzuki Y, Sato S, Kawashima Y, Hirokane G, Morita S, Yokono A, Takahashi S (2003) The effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology 28:1501–1505

    Article  CAS  PubMed  Google Scholar 

  7. Shimoda K, Someya T, Yokono A, Morita S, Hirokane G, Takahashi S, Okawa M (2002) Impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol 22:371–378

    Google Scholar 

  8. Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, Park CW, Shin SG, Flockhart DA, Shin JG (2000) Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 67:567–576

    Google Scholar 

  9. Sindrup SH, Brosen K, Gram LF (1992) Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:288–295

    Google Scholar 

  10. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer (1989) Oxidation of midazolam and triazolam by human liver cytchrome P4503A4. Mol Pharmacol 36:89–96

    CAS  PubMed  Google Scholar 

  11. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994) Inhibitors of alprazolam metabolism in vivo: effect of serotonin-reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23–31

    PubMed  Google Scholar 

  12. Hikida K, Inoue Y, Nouchiand E, Ohkura Y (1990) Determination of Etizolam in human Serum or Plasma Using Automated Cloumn-Switchig High-Performance Liquid Chromatography. Jpn J Clin Chem 19:354–359

    CAS  Google Scholar 

  13. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215–223

    CAS  PubMed  Google Scholar 

  14. Heim M, Meyer UA (1990) Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336 529–532

    Google Scholar 

  15. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825–11829

    CAS  PubMed  Google Scholar 

  16. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population, Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516–520

    CAS  PubMed  Google Scholar 

  17. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570–575

    Google Scholar 

  18. Preskorn S (1994) Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol Suppl 3:13–19

    Google Scholar 

  19. Suzuki A, Otani K, Mihara K, Yasui N, Kondo T, Tokinaga N, Furukori H, Kaneko S, Inoue Y, Hayashi K (1998) Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite. Psychopharmacology (Berl) 135:333–337

    Google Scholar 

  20. Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML, Bertilsson L (2001) Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 52:265–271

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by the Grant in Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Research (#13670991, #13671000, and #15591214).

Author information

Authors and Affiliations

  1. Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, 757 Asahimachidori-ichibancho, 951-8510, Niigata, Japan

    Kazushi Sawamura, Yutaro Suzuki & Toshiyuki Someya

Authors
  1. Kazushi Sawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshiyuki Someya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiyuki Someya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sawamura, K., Suzuki, Y. & Someya, T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 60, 553–557 (2004). https://doi.org/10.1007/s00228-004-0792-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0792-6

Keywords

Search

Navigation